Another reason to profile Neuro-onc patients at diagnosis. RNA fusion panel should always be alongside the DNA component for finding targets.

BRAF fusions are increasingly being targeted in early phase trials. Great to see this break into the standard of care for #braincancer

So happy to finally share! Amazing project and amazing team behind this! Here's to the next steps - translating it into the clinic to really help patients get a quicker diagnosis. World CUP Awareness CUP Foundation CRUK National Biomarker Centre Natalie Cook 💙 NIHR Manchester Biomedical Research Centre nature.com/articles/s4146…

Recent slew of nature papers all using CAR-T in #glioblastoma . Very mixed results - a few patients with objective responses here, even a CR, but most SD or worse.

More needs to be learned here; what makes some respond and others don't?

nature.com/articles/s4159…

Great example of making treatment work for patients and sustaining QoL. Fewer symptoms, fewer dose changes, low intensity intervention, at low cost.

People prescribing #Capecitabine should give this a go.

Great first day at #ESMOTAT24 ESMO - Eur. Oncology with fascinating important talks, new friends and a poster prize to top it off!

Looking forward to what the rest of the meeting brings 💊

Very proud of our work being poster-presented at #ESMOTAT24 by my friend and collaborator Sarah Rae tomorrow!

Keen for stronger research links between northern institutions Manchester ECMC Sir Bobby Robson Cancer Trials Research Centre ECMC Network

Additional last authors Dr Donna Graham and Ruth Plummer

Very thrilling to see further activity in H3K27M mutant diffuse gliomas which predominantly affects children. Small numbers but very rare subset of the disease.

Excited for Ph3 results to come from NCT05580562 in the next few years!

Brain Cancer Lab EANO SNO

A significant milestone for cellular therapy for solid tumour: The much awaited FDA approval of autologous TIL therapy for 2nd line treatment of patients with advanced melanoma.

Very exciting chemistry to convert a KRAS G12C inhibitor to pan-KRASi; and validated in vitro.

Targeting #KRAS across all variants would be game changing, as opposed to single mutation inhibitors Ie. G12C only. It's low vs. high yield

#precisiononcology

nature.com/articles/s4158…

Insane to see such a high TMB (>400!), let alone in such a rare cancer. It's hard to speculate the value of #immunotherapy from n=1, but continuous response on treatment is positive.

Again proves the value of #genomics testing in #braincancer

ascopubs.org/doi/10.1200/PO…

Happy New Badge Day 💐

I'm thrilled to start at Peter Mac as a Neuro-oncology fellow and research collaborator in the Walter and Eliza Hall Institute.

Thank you Peter Mac Cancer Centre BrainCancerCentre WEHI (Walter and Eliza Hall Institute) and most importantly Jim Whittle for the opportunity.

Let's get to work.

It was exciting to be a part of #JING last year, and meet the engaged and passionate #CancerResearch community.

I would love to contribute to something as important and training the next generation later in my career.

Thanks for growing the skillset! ECMC Network